Wallace C A, Smith A L, Sherry D D
Department of Pediatrics, University of Washington, Seattle.
J Rheumatol. 1993 Oct;20(10):1764-8.
To investigate the potential interaction of naproxen and methotrexate (MTX) in children with juvenile rheumatoid arthritis (JRA).
Nine children with JRA served as their own control taking their usual doses of MTX (0.22-1.02 mg/kg/week) and naproxen (14.6-18.8 mg/kg/day) separately and in combination.
MTX affected a > or = 30% change in naproxen kinetics in 6/8 patients, while naproxen altered MTX kinetics by > or = 30% in 4/9 patients.
MTX can alter nonsteroidal antiinflammatory drug (NSAID) kinetics in children with JRA and NSAID can alter MTX kinetics. NSAID toxicity should be considered when assessing adverse reactions in patients receiving the combination treatment of MTX and NSAID:
研究萘普生与甲氨蝶呤（MTX）在幼年类风湿关节炎（JRA）患儿中的潜在相互作用。
9例JRA患儿作为自身对照，分别单独及联合服用常用剂量的MTX（0.22 - 1.02毫克/千克/周）和萘普生（14.6 - 18.8毫克/千克/天）。
8例患者中有6例MTX使萘普生动力学改变≥30%，9例患者中有4例萘普生使MTX动力学改变≥30%。
MTX可改变JRA患儿非甾体抗炎药（NSAID）的动力学，NSAID也可改变MTX的动力学。在评估接受MTX与NSAID联合治疗患者的不良反应时，应考虑NSAID的毒性。
